Biontech Se Adr Share Price (0A3M)

Https://www.google.com/search?q=nasdaq+intel&client=ms-android-samsung-gs-rev1&hs=siip&sca_esv=cd246a25237b15d7&biw=360&bih=612&sxsrf=ANbL-n6HWdv9wwVcyHQhUNDE5ZKD1NdcpA%3A1776363941341&ei=pSnhaeq_FJqihbIP_fGUaA&oq=nasdaq+intel&gs_lp=EhNtb2JpbGUtZ3dzLXdpei1zZXJwIgxuYXNkYXEgaW50ZWwyEhAjGIAEGCcYigUYRhj6ARijBTIKECMYgAQYJxiKBTIFEAAYgAQyBRAAGIAEMgUQABiABDITECMYgAQYigUYRhj6ARiMBdgBAUiRRlCYCVjAQnADeAGQAQCYAaUBoAH5D6oBBDkuMTC4AQPIAQD4AQGYAhWgArgUqAItwgIKEAAYsAMY1gQYR8ICCxAAGIAEGJECGIoFwgIGEAAYFhgewgIREAAYgAQYkQIYsQMYgwEYigXCAgsQABiABBixAxiDAcICDhAAGIAEGLEDGIMBGIoFwgIHECMYJxjqAsICEBAAGAMYtAIY6gIYjwHYAQHCAhAQLhgDGLQCGOoCGI8B2AEBwgIKEAAYgAQYQxiKBcICEBAAGIAEGLEDGEMYgwEYigWYAz_xBVyhpSTpvAbeiAYBkAYIugYECAEYE5IHBDUuMTagB4DAAbIHBDIuMTa4B8ATwgcIMy02LjEwLjXIB6IFgAgA&sclient=mobile-gws-wiz-serp

Https://www.bbc.co.uk/news/articles/ce806ndv8neo

A 67-year-old man has become the first person in the UK to try what doctors hope will be a revolutionary new treatment for lung cancer - a vaccine that tells the body how to fight and kill the disease.

It uses the same mRNA technology as some Covid jabs to give instructions to the immune system.

The early-stage trial in which Janusz Racz is taking part will check the shot is safe.

Some 34 research sites in seven countries, including University College London in the UK, will recruit 130 patients to try it.

Highly targeted

The treatment should specifically target cancer cells for destruction rather than healthy ones, hopefully meaning fewer side effects.

It contains information about several markers found on the surface of lung cancer cells to teach the patient's immune system what to find and fight.

The BNT116 vaccine, made by German biotechnology company BioNTech, could be a game-changer, say experts.

Looks like the only ones buying this stock are Biontech themselves...

NEW YORK & MAINZ, Germany -- (Business Wire)

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a new vaccine supply agreement with the U.S. government to support the continued fight against COVID-19. Under the agreement, the U.S. government will receive 105 million doses (30 microg, 10 microg and 3 microg). This may include adult Omicron-adapted COVID-19 vaccines, subject to authorization from the U.S. Food and Drug Administration (FDA). The doses are planned to be delivered as soon as late summer 2022 and continue into the fourth quarter of this year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220629005833/en/

The U.S. government will pay the companies $3.2 billion upon receipt of the first 105 million doses. Under this agreement, the U.S. government also has the option to purchase up to 195 million additional doses, bringing the total number of potential doses to 300 million.

"As the virus evolves, this new agreement will help ensure people across the country have access to vaccines that may provide protection against current and future variants," said Albert Bourla, Chairman and Chief Executive Officer, Pfizer. "Vaccines have been and will remain critical to protecting people of all ages against COVID-19. We remain proud of our long-term partnership with the U.S. government in helping to address this pandemic, and of the ongoing impact of vaccination efforts in the U.S. and around the world."

"This agreement will provide additional doses for U.S. residents and help cope with the next COVID-19 wave. Pending regulatory authorization, it will also include an Omicron-adapted vaccine, which we believe is important to address the rapidly spreading Omicron variant," said Sean Marett, Chief Business and Chief Commercial Officer of BioNTech. "We appreciate the continued partnership of the U.S. government in our shared goal to help end this pandemic."

Not much shareholder value here, they will buy the shares back after a 20 % down kicking and present that as returning shareholder value ! If they have any dignity they should buy the shares back at the price before the fall, now that would be returning shareholder value !